Abstract
A randomized study of 12 treated patients and seven controls was conducted in order to evaluate HPA-23 anti-HIV activity in HIV-infected patients. The antiviral activity was assessed by determining HIV p24 antigenemia. A persistence or even increase in antigenemia was shown in treated patients and thrombocytopenia was observed in nine out of the 12 patients. This suggests that HPA-23 should not be used in anti-HIV therapy.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Antimony / adverse effects
-
Antimony / pharmacology
-
Antimony / therapeutic use*
-
Antiviral Agents / adverse effects
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
Drug Evaluation
-
Follow-Up Studies
-
Gene Products, gag / blood*
-
HIV Antigens / blood*
-
HIV Core Protein p24
-
HIV Infections / blood
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
Humans
-
Leukocyte Count
-
Platelet Count
-
Random Allocation
-
Reverse Transcriptase Inhibitors
-
Thrombocytopenia / chemically induced
-
Tungsten / adverse effects
-
Tungsten / pharmacology
-
Tungsten / therapeutic use*
-
Tungsten Compounds*
-
Viral Core Proteins / blood*
Substances
-
Antiviral Agents
-
Gene Products, gag
-
HIV Antigens
-
HIV Core Protein p24
-
Reverse Transcriptase Inhibitors
-
Tungsten Compounds
-
Viral Core Proteins
-
ammonium tungsten antimonate hydroxide oxide
-
Antimony
-
Tungsten